10-Q: Bio-Techne Reports Mixed Q3 Results Amidst Restructuring and Acquisition Impacts

Bio-Techne's third-quarter results show a slight revenue increase but a significant drop in net earnings due to restructuring, acquisition costs, and unfavorable volume in Protein Sciences.

Summary

• Bio-Techne's net sales for the quarter ended March 31, 2024, increased by 3% to $303.4 million compared to the same period last year.
• Organic revenue grew by 2% for the quarter, with acquisitions contributing 1%.
• Net earnings attributable to Bio-Techne decreased to $49.1 million for the quarter, down from $70.2 million in the prior year.
• The decrease in net earnings is primarily due to the acquisition of Lunaphore, CEO transition costs, restructuring charges, and unfavorable volume within the Protein Sciences segment.
• For the nine months ended March 31, 2024, net sales increased by 2% to $853.0 million, while net earnings attributable to Bio-Techne decreased to $127.5 million from $209.8 million in the prior year.
• The prior year's net earnings were positively impacted by non-recurring gains from the sale of investments.
• Gross margins for the quarter were 67.4%, down from 68.7% in the prior year, and 66.4% for the nine months, down from 67.6% in the prior year.
• Adjusted gross margins, excluding certain items, were 71.9% for the quarter and 71.0% for the nine months.
• Selling, general, and administrative expenses increased by 13% for the quarter and 14% for the nine months, primarily due to the Lunaphore acquisition, CEO transition costs, and restructuring charges.
• Research and development expenses increased by 13% for the quarter and 5% for the nine months, driven by the Lunaphore acquisition and strategic growth investments.
• The company is undergoing restructuring actions that impacted approximately 4% of its global workforce and expects to incur costs through the first half of fiscal 2025.
• Bio-Techne acquired Lunaphore Technologies SA for $169.7 million in July 2023, adding spatial biology instruments to its portfolio.

Sentiment

Score: 4

Explanation: The document presents mixed results with a decrease in net earnings and gross margins, offset by a slight increase in revenue and strategic acquisitions. The restructuring and cost-cutting measures indicate some challenges, leading to a slightly negative sentiment.

Positives

• Net sales increased by 3% for the quarter and 2% for the nine months.
• Organic revenue grew by 2% for the quarter.
• The acquisition of Lunaphore Technologies SA expands the company's spatial biology offerings.
• The company generated $223.5 million in cash from operating activities in the nine months ended March 31, 2024, compared to $171.0 million in the same period last year.

Negatives

• Net earnings attributable to Bio-Techne decreased significantly for both the quarter and nine months ended March 31, 2024.
• Gross margins decreased for both the quarter and nine months ended March 31, 2024.
• Selling, general, and administrative expenses increased significantly for both the quarter and nine months ended March 31, 2024.
• The Protein Sciences segment experienced a decrease in sales and operating margin.
• The Diagnostics and Genomics segment's operating margin decreased.

Risks

• The company is undergoing restructuring actions that may incur costs through the first half of fiscal 2025.
• The integration of the newly acquired Lunaphore business may present challenges.
• Unfavorable volume and product mix impacted gross margins.
• The company is exposed to foreign currency exchange rate fluctuations.
• The company's performance is subject to general national and international economic, political, and regulatory conditions.

Future Outlook

Management expects to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit. Capital expenditures for the remainder of fiscal 2024 are expected to be approximately $16 million. The company is currently forecasting the second option payment of approximately $1 billion plus potential contingent consideration to occur between fiscal 2026 and fiscal 2028 related to the Wilson Wolf acquisition.

Management Comments

• The company's key business strategies for long-term growth and profitability continue to be geographic expansion, core product innovation, acquisitions, and talent retention and development.
• The company is integrating consideration of greenhouse gas emissions and other environmental variables into its key business strategies.
• The company strives to innovate and improve all aspects of Bio-Techne's operations, including reducing the environmental impacts of our manufacturing operations.

Industry Context

The acquisition of Lunaphore aligns with the broader industry trend of increasing focus on spatial biology and advanced tissue-based assays. The company's restructuring efforts reflect a common strategy among life science companies to optimize operations and improve profitability in response to market conditions and growth opportunities.

Comparison to Industry Standards

• Bio-Techne's revenue growth of 3% is moderate compared to some high-growth biotech companies, but it is in line with established players in the life sciences tools and diagnostics sector.
• The decrease in net earnings and gross margin is a concern, as many competitors are focused on improving profitability.
• Companies like Danaher and Thermo Fisher Scientific, which also operate in the life sciences tools and diagnostics space, have shown more robust revenue growth and profitability in recent quarters.
• The restructuring actions are similar to those taken by other companies in the industry to streamline operations and reduce costs.
• The acquisition of Lunaphore is a strategic move to compete with companies like 10x Genomics and NanoString Technologies in the rapidly growing spatial biology market.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net earnings and gross margins.
• Employees may be affected by the ongoing restructuring actions.
• Customers may benefit from the company's expanded product portfolio through the acquisition of Lunaphore.
• Suppliers may be impacted by changes in the company's operations due to restructuring.

Next Steps

• The company expects to incur costs related to restructuring actions through the first half of fiscal 2025.
• The company will continue to integrate Lunaphore Technologies SA into its operations.
• The company will continue to monitor and manage its exposure to foreign currency exchange rate fluctuations.
• The company will continue to evaluate and refine its non-GAAP financial measures.

Key Dates

Keywords

Bio-Techne, biotechnology, reagents, instruments, diagnostics, genomics, protein sciences, spatial biology, Lunaphore, restructuring, acquisition, financial results, net sales, net earnings, gross margin